IMA950 is a multi-peptide vaccine composed of 9 MHC class I restricted peptides and 2 MHC class II-restricted peptides, c-Met and survivin, all of them overexpressed in GBM cells.72,73 The safety and immunogenicity of IMA950 with adjuvant poly-ICLC were assessed in a phase I/II trial (NCT01920191) in 16 patients, with an mOS of 19 months 73. Here, HLA-C is linked to glioblastoma.